全文获取类型
收费全文 | 182篇 |
免费 | 9篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 1篇 |
妇产科学 | 7篇 |
基础医学 | 19篇 |
口腔科学 | 3篇 |
临床医学 | 14篇 |
内科学 | 65篇 |
神经病学 | 34篇 |
特种医学 | 6篇 |
外科学 | 9篇 |
综合类 | 2篇 |
预防医学 | 10篇 |
药学 | 6篇 |
肿瘤学 | 1篇 |
出版年
2022年 | 2篇 |
2019年 | 3篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2015年 | 4篇 |
2014年 | 6篇 |
2013年 | 9篇 |
2012年 | 5篇 |
2011年 | 5篇 |
2010年 | 6篇 |
2009年 | 7篇 |
2008年 | 11篇 |
2007年 | 8篇 |
2006年 | 5篇 |
2005年 | 5篇 |
2004年 | 6篇 |
2003年 | 3篇 |
2002年 | 2篇 |
2001年 | 5篇 |
1997年 | 3篇 |
1991年 | 3篇 |
1990年 | 6篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 2篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1979年 | 4篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1974年 | 5篇 |
1973年 | 3篇 |
1972年 | 2篇 |
1971年 | 3篇 |
1970年 | 3篇 |
1968年 | 1篇 |
1965年 | 1篇 |
1878年 | 2篇 |
1877年 | 3篇 |
1876年 | 2篇 |
1869年 | 1篇 |
1868年 | 3篇 |
1867年 | 2篇 |
1864年 | 1篇 |
1863年 | 1篇 |
排序方式: 共有191条查询结果,搜索用时 593 毫秒
1.
2.
3.
4.
Linda L. Toche-Manley PhD Laura Dietzen MS Jesse Nankin MA Astrid Beigel PhD 《The journal of behavioral health services & research》2013,40(3):317-329
Outcomes management technology holds great promise for improving the quality of services provided to youth in the child welfare system. Advantages include better detection of behavioral health and trauma-related issues, early indicators of case progress or risk of failure, and program- and system-level learning. Yet organizational barriers to implementation persist. Attention is spent in this paper on addressing these barriers so the use of outcomes management technology becomes a common practice. A model for predicting resiliency is presented, along with case examples demonstrating its potential use for treatment planning and monitoring progress. 相似文献
5.
Aspirin withdrawal in patients treated with ticagrelor presenting with non‐ST elevation myocardial infarction 下载免费PDF全文
R. Beigel I. Mazin E. Koifman M. Shechter H. Pres N. Shlomo N. Rosenberg E. Asher S. Matetzky 《Journal of thrombosis and haemostasis》2018,16(4):663-669
Essentials
- Strong P2Y12 blockade may cause platelet inhibition that is only minimally enhanced by aspirin.
- We evaluated aspirin withdrawal on platelet reactivity in ticagrelor treated patients.
- Aspirin withdrawal resulted in increased platelet reactivity to arachidonic acid.
- Aspirin withdrawal caused little difference in adenosine diphosphate‐induced platelet aggregation.
Summary
Background
Recent studies have shown that the thromboxane A2‐dependent pathway is dependent on the ADP–P2Y12 pathway, and that strong P2Y12 receptor blockade alone causes inhibition of platelet aggregation that is minimally enhanced by aspirin. Data from the PLATO trial suggested that, among ticagrelor‐treated patients, high‐dose versus low‐dose (< 100 mg day?1) aspirin is associated with an increased risk fof ischemic events.Objectives
To evaluate the impact of aspirin withdrawal on platelet reactivity in acute coronary syndrome (ACS) patients treated with a potent P2Y12 blocker.Patients/Methods
This was a current prospective, randomized, placebo‐controlled, double‐blind, cross‐over study. The study population comprised 22 consecutive ACS patients who underwent percutaneous coronary intervention and were treated with aspirin (100 mg day?1) and ticagrelor. Thirty days post‐ACS, open‐label aspirin was stopped, and patients were randomized to either blinded aspirin or placebo for 2 weeks, with each patient crossing over to the other arm for an additional 2 weeks. Platelet reactivity to arachidonic acid and ADP determined with light‐transmission aggregometry (LTA) and VerifyNow was evaluated at baseline, and 2 weeks and 4 weeks later.Results
Aspirin withdrawal resulted in an increase in arachidonic‐acid induced platelet reactivity as determined with both LTA (77.0% ± 11.3% versus 20.8% ± 4.4%) and VerifyNow (607.7 ± 10.6 aspirin reaction units [ARU] versus 408.5 ± 14.4 ARU). Platelet response to ADP, as determined with both LTA and VerifyNow, did not differ with either aspirin or placebo (32.9% ± 2.6% versus 35.8% ± 3.6%, and 33.5 ± 6.4 P2Y12 reaction units (PRU) versus 29.6 ± 5.7 PRU, respectively).Conclusions
Aspirin withdrawal early post‐ACS results in increased platelet reactivity in response to arachidonic acid, despite concomitant treatment with the potent P2Y12 blocker ticagrelor.6.
Elad Asher Arsalan Abu-Much Nicola L. Bragazzi Anan Younis Arwa Younis Eyas Masalha Ronen Goldkorn Israel Mazin Paul Fefer Israel M. Barbash Amit Segev Roy Beigel Shlomi Matetzky 《Journal of cardiology》2021,77(4):375-379
BackgroundPlatelet function testing (PFT) in patients treated with P2Y12 inhibitors has been widely evaluated for the prediction of stent thrombosis, myocardial infarction, and bleeding events following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). Thus, PFT-guided treatment could positively affect patient outcomes. Data regarding clinical parameters for predicting platelet reactivity in ACS patients are limited. Therefore, our study aims to evaluate CHADS2 and CHA2DS2-VASc scores as predictors for platelet reactivity in ACS patients.MethodsTwo hundred and ninety-one consecutive patients who underwent PCI and were treated with aspirin and clopidogrel due to ACS were tested for their CHADS2, CHA2DS2-VASc scores and platelet reactivity using adenosine diphosphate (ADP)-induced aggregation (conventional aggregometry). Patients were classified into groups according to their CHADS2 and CHA2DS2-VASc scores. Low-risk group (0–1 score) for CHADS2 and CHA2DS2-VASc scores and high-risk group (2–6, 2–9) for CHADS2 and CHA2DS2-VASc scores, respectively. Furthermore, platelet reactivity in each group were compared (low CHADS2 group vs high CHADS2 group, and low CHA2DS2-VASc vs high CHA2DS2-VASc). Platelet reactivity was defined as low platelet reactivity (<19 U), optimal platelet reactivity [(OPR); 19–46 U], and high on-treatment platelet reactivity [(HPR); >46 U]. Thereafter receiver operating characteristic curve analysis was conducted to verify whether CHADS2 and CHA2DS2-VASc scores could predict platelet reactivity.ResultsLow CHADS2 and CHA2DS2-VASc scores were significantly correlated with lower mean platelet ADP-induced aggregation as compared with high CHADS2 and CHA2DS2-VASc scores [45.5 U (± 16) vs. 54.8 U (±15) and 44.2 U (±16) vs. 51.0 U (±17), respectively, p = 0.01 for both].ConclusionIn ACS patients treated with clopidogrel following PCI, high CHADS2 and CHA2DS2-VASc scores correlated with HPR and lower scores correlated with OPR. Further studies are needed to evaluate our findings’ clinical implications. 相似文献
7.
8.
Beigel R Hod H Fefer P Asher E Novikov I Shenkman B Savion N Varon D Matetzky S 《The American journal of cardiology》2011,(3):339-342
Aspirin failure, defined as occurrence of an acute coronary syndrome despite aspirin use, has been associated with a higher cardiovascular risk profile and worse prognosis. Whether this phenomenon is a manifestation of patient characteristics or failure of adequate platelet inhibition by aspirin has never been studied. We evaluated 174 consecutive patients with acute myocardial infarction. Of them, 118 (68%) were aspirin naive and 56 (32%) were regarded as having aspirin failure. Platelet function was analyzed after ≥72 hours of aspirin therapy in all patients. Platelet reactivity was studied by light-transmitted aggregometry and under flow conditions. Six-month incidence of major adverse coronary events (death, recurrent acute coronary syndrome, and/or stroke) was determined. Those with aspirin failure were older (p = 0.002), more hypertensive (p <0.001), more hyperlipidemic (p <0.001), and more likely to have had a previous cardiovascular event and/or procedure (p <0.001). Cumulative 6-month major adverse coronary events were higher in the aspirin-failure group (14.3% vs 2.5% p <0.01). Patients with aspirin failure had lower arachidonic acid-induced platelet aggregation (32 ± 24 vs 45 ± 30, p = 0.003) after aspirin therapy compared to their aspirin-naive counterparts. However, this was not significant after adjusting for differences in baseline characteristics (p = 0.82). Similarly, there were no significant differences in adenosine diphosphate-induced platelet aggregation and platelet deposition under flow conditions. In conclusion, our results suggest that aspirin failure is merely a marker of higher-risk patient profiles and not a manifestation of inadequate platelet response to aspirin therapy. 相似文献
9.
Y Beigel J George L Leibovici A Mattityahu S Sclarovsky L Blieden 《Acta paediatrica (Oslo, Norway : 1992)》1993,82(2):162-165
In order to assess the value of family history of premature coronary artery disease as a criterion for coronary risk factor screening, a group of 53 children with such a family history was selected. We determined various coronary risk factors in these children in comparison to 33 controls. Statistically significant differences were observed in apoprotein concentrations but not in concentrations of lipids, lipoproteins or glucose, or in blood pressure or body mass index. The ratio between apoprotein B and apoprotein A1 was the best discriminator between the two groups. The predictive value of family history is more reliable for detecting abnormal apoprotein ratio than for detection of hypercholestero-lemia. We conclude that if abnormal apoprotein levels during childhood are found to be a valued predictor of premature coronary artery disease, then family history of premature coronary artery disease can be used to select children for determination and assessment of their coronary risk. 相似文献
10.